You need to enable JavaScript to run this app.
Regulatory Recon: FDA Warns Pfizer's Kansas Site AstraZeneca Sells Zoladex Rights for $250M (20 February 2017)
Recon
Regulatory News
Michael Mezher
Recon
Regulatory NewsMichael Mezher
ReconRegulatory NewsMichael Mezher